Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-11-19 | AMRN | Amarin Corp Plcuk | Thero John F | Pres, CEO | S - Sale | $22.65 | -274,454 | 2,342,285 | -10% | -$6,217,371 | ||||||
2019-11-19 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | P - Purchase | $28.17 | +1,960 | 7,967 | +33% | +$55,213 | ||||||
2019-11-21 | EVFM | Evofem Biosciences, Inc. | Pelletier Saundra L | CEO | S - Sale | $6.01 | -10,000 | 414,676 | -2% | -$60,100 | ||||||
| M | 2019-11-20 | EVFM | Evofem Biosciences, Inc. | File Justin J. | CFO | S - Sale | $6.00 | -5,000 | 202,353 | -2% | -$30,000 | |||||
2019-11-20 | VTGN | Vistagen Therapeutics, Inc. | Snodgrass H. Ralph | Pres, CHIEF SCIENTIFIC OFFICER | P - Purchase | $0.34 | +15,000 | 77,724 | +24% | +$5,100 | ||||||
| D | 2019-11-19 | ARDX | Ardelyx, Inc. | Grammer Elizabeth A | EVP, GC | S - Sale+OE | $7.00 | -5,000 | 120,219 | -4% | -$35,000 | |||||
| D | 2019-11-20 | TCDA | Tricida, Inc. | Stahl Wilhelm | Chief Tech Officer, SVP | S - Sale+OE | $40.81 | -814 | 14,806 | -5% | -$33,219 | |||||
2019-11-20 | TCDA | Tricida, Inc. | Alpern Robert J | Dir | S - Sale | $40.65 | -2,439 | 138,390 | -2% | -$99,145 | ||||||
2019-11-20 | IONS | Ionis Pharmaceuticals Inc | Klein Joseph III | Dir | S - Sale | $60.00 | -2,000 | 13,595 | -13% | -$120,000 | ||||||
2019-11-20 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | COO, SVP, Translational Med | S - Sale | $60.01 | -5,776 | 16,458 | -26% | -$346,618 | ||||||
2019-11-19 | ARVN | Arvinas, Inc. | Cassidy Sean A | CFO | S - Sale | $32.00 | -10,000 | 159,115 | -6% | -$320,000 | ||||||
| D | 2019-11-19 | CYRX | Cryoport, Inc. | Berman Richard J | Dir | S - Sale+OE | $15.01 | -5,000 | 0 | -100% | -$75,050 | |||||
| D | 2019-11-19 | ACAD | Acadia Pharmaceuticals Inc | Stankovic Srdjan R. | Pres | S - Sale+OE | $46.41 | -2,160 | 6,027 | -26% | -$100,246 | |||||
| M | 2019-11-19 | DRNA | Dicerna Pharmaceuticals Inc | Kolchinsky Peter | Dir | S - Sale | $23.34 | -1,014,193 | 1,442,476 | -41% | -$23,667,124 | |||||
2019-11-19 | NTEC | Intec Pharma Ltd. | Silberman Issac | Dir | S - Sale | $0.50 | -1,000 | 4,000 | -20% | -$504 | ||||||
2019-11-19 | DRNA | Dicerna Pharmaceuticals Inc | Bain Capital Life Sciences Investors, LLC | 10% | S - Sale | $22.03 | -1,750,000 | 5,580,237 | -24% | -$38,552,500 | ||||||
| D | 2019-11-19 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | CEO, Pres | S - Sale+OE | $210.91 | -96,534 | 106,786 | -47% | -$20,360,052 | |||||
| D | 2019-11-19 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, Chief Patient Officer | S - Sale+OE | $215.00 | -5,000 | 53,262 | -9% | -$1,075,000 | |||||
2019-11-20 | LFVN | Lifevantage Corp | Jensen Darren Jay | CEO | S - Sale | $14.13 | -4,500 | 411,470 | -1% | -$63,585 | ||||||
2019-11-20 | PRED | Predictive Technology Group, Inc. | Robinson Bradley C | CEO, 10% | P - Purchase | $0.84 | +10,000 | 20,010,000 | 0% | +$8,400 | ||||||
2019-11-20 | AKBA | Akebia Therapeutics, Inc. | Butler John P. | CEO, Pres | P - Purchase | $3.44 | +50,000 | 1,069,682 | +5% | +$172,000 | ||||||
2019-11-20 | AKBA | Akebia Therapeutics, Inc. | Adams Adrian | Dir | P - Purchase | $3.41 | +50,000 | 63,700 | +365% | +$170,500 | ||||||
| DM | 2019-11-18 | DRNA | Dicerna Pharmaceuticals Inc | Weissman James B | EVP, COO | S - Sale+OE | $23.00 | -40,000 | 14,704 | -73% | -$920,000 | |||||
2019-11-18 | FTSV | Forty Seven, Inc. | Majeti Ravindra | Dir | S - Sale | $10.26 | -15,000 | 1,406,400 | -1% | -$153,915 | ||||||
| D | 2019-11-18 | DRNA | Dicerna Pharmaceuticals Inc | Green John B | CFO | S - Sale+OE | $21.05 | -12,500 | 10,698 | -54% | -$263,125 | |||||
| D | 2019-11-18 | BGNE | Beigene, Ltd. | Liang Howard | CFO, Chief Strategy Officer | S - Sale+OE | $194.34 | -25,000 | 122,317 | -17% | -$4,858,616 | |||||
| D | 2019-11-18 | BGNE | Beigene, Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $194.49 | -1,500 | 291,667 | -1% | -$291,740 | |||||
2019-11-18 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $17.97 | -3,960 | 291,697 | -1% | -$71,161 | ||||||
2019-11-18 | NKTR | Nektar Therapeutics | Thomsen Jillian B. | SVP, Chief Accounting Officer | S - Sale | $17.97 | -2,713 | 160,441 | -2% | -$48,753 | ||||||
2019-11-18 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $17.97 | -13,556 | 299,629 | -4% | -$243,601 | ||||||
2019-11-18 | NKTR | Nektar Therapeutics | Labrucherie Gil M | SVP, COO, CFO | S - Sale | $17.97 | -8,863 | 219,009 | -4% | -$159,268 | ||||||
2019-11-18 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.39 | +1,000 | 7,127,556 | 0% | +$390 | ||||||
| DM | 2019-11-18 | GBT | Global Blood Therapeutics, Inc. | Lehrer-Graiwer Joshua | Chief Medical Officer | S - Sale+OE | $54.60 | -7,218 | 0 | -100% | -$394,123 | |||||
2019-11-18 | ADMP | Adamis Pharmaceuticals Corp | Hopkins Robert O | CFO | S - Sale | $0.83 | -7,347 | 325,900 | -2% | -$6,099 | ||||||
2019-11-18 | ADMP | Adamis Pharmaceuticals Corp | Moss Ronald B. | Chief Medical Officer | S - Sale | $0.85 | -8,448 | 259,424 | -3% | -$7,198 | ||||||
2019-11-18 | ADMP | Adamis Pharmaceuticals Corp | Daniels Karen K. | VP of Operations | S - Sale | $0.83 | -5,421 | 163,689 | -3% | -$4,499 | ||||||
2019-11-18 | ADMP | Adamis Pharmaceuticals Corp | Marguglio David J. | SVP, Chief Business Officer | S - Sale | $0.87 | -8,283 | 371,191 | -2% | -$7,197 | ||||||
2019-11-18 | ADMP | Adamis Pharmaceuticals Corp | Carlo Dennis J Phd | Pres,amp; CEO | S - Sale | $0.84 | -10,760 | 343,170 | -3% | -$8,999 | ||||||
2019-11-19 | ALIM | Alimera Sciences Inc | Largent James R | Dir | P - Purchase | $5.11 | +3,000 | 3,000 | New | +$15,344 | ||||||
| DM | 2019-11-18 | BPMC | Blueprint Medicines Corp | Albers Jeffrey W. | CEO, Pres | S - Sale+OE | $74.91 | -20,000 | 48,961 | -29% | -$1,498,285 | |||||
2019-11-18 | ELAN | Elanco Animal Health Inc | Urbanek David Alan | See Remarks | P - Purchase | $26.25 | +228 | 49,585 | 0% | +$5,986 | ||||||
| D | 2019-11-19 | ZTS | Zoetis Inc. | Alaix Juan Ramon | CEO | S - Sale+OE | $119.13 | -50,000 | 96,013 | -34% | -$5,956,500 | |||||
| D | 2019-11-19 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale+OE | $118.99 | -4,463 | 28,727 | -13% | -$531,052 | |||||
| M | 2019-11-18 | NATR | Natures Sunshine Products Inc | Wynnefield Partners Small Cap Value LP | 10% | P - Purchase | $9.64 | +42,905 | 2,368,881 | +2% | +$413,733 | |||||
| D | 2019-11-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Sharp Phillip A | Dir | S - Sale+OE | $91.71 | -15,000 | 266,899 | -5% | -$1,375,662 | |||||
| D | 2019-11-18 | ZTS | Zoetis Inc. | Chen Heidi C. | EVP | S - Sale+OE | $118.86 | -11,425 | 11,463 | -50% | -$1,357,976 | |||||
| D | 2019-11-18 | INSM | Insmed Inc | Goll John | Chief Accounting Officer | S - Sale+OE | $20.04 | -25,000 | 7,322 | -77% | -$501,000 | |||||
2019-11-20 | CLSN | Celsion Corp | Martinez Alberto R Jr | Dir | P - Purchase | $1.42 | +6,000 | 40,000 | +18% | +$8,520 | ||||||
2019-11-19 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $115.06 | -205,000 | 116,005,304 | 0% | -$23,586,776 | ||||||
2019-11-19 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.47 | +100,000 | 221,171,633 | 0% | +$146,651 | ||||||
2019-11-15 | NXTC | Nextcure, Inc. | Sofinnova Venture Partners Ix, L.P. | 10% | P - Purchase | $36.75 | +150,000 | 2,671,856 | +6% | +$5,512,500 | ||||||
| DM | 2019-11-15 | BDSI | Biodelivery Sciences International Inc | Broadfin Healthcare Master Fund Ltd | Dir | S - Sale+OE | $5.98 | -4,000,000 | 4,300,066 | -48% | -$23,903,254 | |||||
2019-11-19 | ICPT | Intercept Pharmaceuticals, Inc. | Weyer Christian | EVP, Research, Development | S - Sale | $85.00 | -1,550 | 15,759 | -9% | -$131,750 | ||||||
| D | 2019-11-19 | ICPT | Intercept Pharmaceuticals, Inc. | Sullivan Ryan T | GC, Secretary | S - Sale+OE | $85.00 | -12,154 | 21,889 | -36% | -$1,033,090 | |||||
| D | 2019-11-15 | FOLD | Amicus Therapeutics, Inc. | Crowley John F | COB, CEO | S - Sale+OE | $9.52 | -20,000 | 800,589 | -2% | -$190,390 | |||||
| DM | 2019-11-15 | AVDL | Avadel Pharmaceuticals Plc | Glass Geoffrey Michael | Dir | P - Purchase | $4.99 | +20,000 | 47,900 | +72% | +$99,800 | |||||
| D | 2019-11-15 | AVDL | Avadel Pharmaceuticals Plc | Divis Greg J | CEO | P - Purchase | $5.13 | +19,000 | 86,100 | +28% | +$97,470 | |||||
| M | 2019-11-18 | TCDA | Tricida, Inc. | Parker Geoffrey M. | Chief Fin. Officer, SVP | P - Purchase | $34.30 | +20,000 | 191,122 | +12% | +$686,016 | |||||
| D | 2019-11-15 | AVDL | Avadel Pharmaceuticals Plc | Ende Eric J | Dir | P - Purchase | $4.98 | +10,000 | 37,900 | +36% | +$49,762 | |||||
| D | 2019-11-15 | BDSI | Biodelivery Sciences International Inc | Vollins James | See Remarks | S - Sale+OE | $6.09 | -29,825 | 0 | -100% | -$181,634 | |||||
2019-11-18 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.00 | -20,000 | 26,110,521 | 0% | -$20,000 | ||||||
2019-11-15 | BDSI | Biodelivery Sciences International Inc | Davis Todd C | Dir | S - Sale | $6.11 | -200,000 | 237,914 | -46% | -$1,222,000 | ||||||
2019-11-18 | BDSI | Biodelivery Sciences International Inc | Plesha Scott M. | See Remarks | S - Sale | $6.06 | -25,000 | 257,336 | -9% | -$151,500 | ||||||
2019-11-15 | TORC | Restorbio, Inc. | Puretech Health LLC | 10% | S - Sale | $1.25 | -531,040 | 9,269,356 | -5% | -$661,941 | ||||||
| A | 2019-11-01 | ALIM | Alimera Sciences Inc | Jones John Philip | CFO | P - Purchase | $0.30 | +10,000 | 124,590 | +9% | +$3,008 | |||||
2019-11-19 | SNGX | Soligenix, Inc. | Zeldis Jerome B | Dir | P - Purchase | $0.93 | +2,000 | 22,917 | +10% | +$1,850 | ||||||
2019-11-19 | SNGX | Soligenix, Inc. | Schaber Christopher J | COB, CEO, Pres | P - Purchase | $0.93 | +10,770 | 53,095 | +25% | +$10,016 | ||||||
| A | 2019-11-14 | ALIM | Alimera Sciences Inc | Eiswirth Richard S Jr | Pres, CEO | P - Purchase | $0.30 | +100,000 | 463,901 | +27% | +$29,890 | |||||
2019-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | SVP, CRO | S - Sale | $205.95 | -5 | 7,252 | 0% | -$1,030 | ||||||
| D | 2019-11-15 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale+OE | $75.00 | -415 | 0 | -100% | -$31,125 | |||||
| D | 2019-11-15 | PCRX | Pacira Biosciences, Inc. | Stack David M | CEO, COB | S - Sale+OE | $42.81 | -70,000 | 162,103 | -30% | -$2,996,700 | |||||
2019-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, Chief Patient Officer | S - Sale | $205.95 | -57 | 53,262 | 0% | -$11,739 | ||||||
2019-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale | $205.95 | -84 | 35,003 | 0% | -$17,300 | ||||||
| DM | 2019-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | CEO, Pres | S - Sale+OE | $210.00 | -9,434 | 106,786 | -8% | -$1,981,140 | |||||
2019-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | EVP, CMO | S - Sale | $205.95 | -61 | 13,098 | 0% | -$12,563 | ||||||
2019-11-18 | EBS | Emergent Biosolutions Inc. | Zoon Kathryn C | Dir | S - Sale | $54.31 | -1,000 | 17,412 | -5% | -$54,314 | ||||||
2019-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Arbuckle Stuart A | EVP\Chief Commercial Officer | S - Sale | $205.95 | -19 | 33,380 | 0% | -$3,913 | ||||||
| D | 2019-11-18 | CWBR | Cohbar, Inc. | Biunno Jeffrey Francis | CFO, Treasurer, Secretary | S - Sale+OE | $1.95 | -5,000 | 11,000 | -31% | -$9,750 | |||||
2019-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Global Research, CSO | S - Sale | $205.95 | -60 | 31,553 | 0% | -$12,357 | ||||||
| M | 2019-11-15 | EIDX | Eidos Therapeutics, Inc. | Fox Jonathan C | See Remarks | S - Sale | $48.65 | -15,000 | 474,377 | -3% | -$729,703 | |||||
2019-11-18 | YMAB | Y-Mabs Therapeutics, Inc. | Gad Thomas | Pres, COB | S - Sale | $28.41 | -4,000 | 1,906,557 | 0% | -$113,658 | ||||||
2019-11-15 | CYCN | Cyclerion Therapeutics, Inc. | Busch Andreas | Chief Innovation Officer | P - Purchase | $1.82 | +125,000 | 125,000 | New | +$227,500 | ||||||
2019-11-18 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $114.00 | -10,598 | 116,210,304 | 0% | -$1,208,172 | ||||||
2019-11-15 | MTNB | Matinas Biopharma Holdings, Inc. | Lepore Patrick G | Dir | P - Purchase | $1.06 | +100,000 | 300,000 | +50% | +$105,530 | ||||||
| D | 2019-11-15 | QURE | Uniqure N.V. | Kuta Alexander Edward III | EVP, Operations | S - Sale+OE | $52.08 | -4,000 | 41,578 | -9% | -$208,310 | |||||
2019-11-18 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.48 | +100,000 | 221,071,633 | 0% | +$147,925 | ||||||
2019-11-15 | URGN | Urogen Pharma Ltd. | Barrett Elizabeth A. | CEO | P - Purchase | $26.00 | +1,548 | 1,548 | New | +$40,248 | ||||||
| M | 2019-11-14 | AGRX | Agile Therapeutics Inc | Perceptive Advisors LLC | 10% | P - Purchase | $1.68 | +5,768,815 | 11,919,925 | +94% | +$9,675,987 | |||||
2019-11-15 | ISEE | Iveric Bio, Inc. | Sblendorio Glenn | Pres, CEO | P - Purchase | $3.12 | +15,000 | 114,354 | +15% | +$46,851 | ||||||
| DM | 2019-11-14 | GBT | Global Blood Therapeutics, Inc. | Lehrer-Graiwer Joshua | Chief Medical Officer | S - Sale+OE | $50.01 | -10,277 | 0 | -100% | -$513,901 | |||||
| M | 2019-11-14 | BGNE | Beigene, Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale | $194.63 | -13,000 | 7,685,002 | 0% | -$2,530,198 | |||||
2019-11-18 | RETA | Reata Pharmaceuticals Inc | Traweek James W Jr | 10% | P - Purchase | $183.00 | +40,218 | 3,091,186 | +1% | +$7,359,894 | ||||||
2019-11-15 | BGNE | Beigene, Ltd. | Wu Xiaobin | Pres, GM China | S - Sale | $202.05 | -1,000 | 1,483,956 | 0% | -$202,050 | ||||||
2019-11-18 | RETA | Reata Pharmaceuticals Inc | McGaughy R Kent Jr | Dir, 10% | P - Purchase | $183.00 | +40,218 | 3,096,181 | +1% | +$7,359,894 | ||||||
2019-11-18 | RETA | Reata Pharmaceuticals Inc | Cpmg Inc | Dir, 10% | P - Purchase | $183.00 | +40,218 | 3,063,567 | +1% | +$7,359,894 | ||||||
| D | 2019-11-15 | RARX | Ra Pharmaceuticals, Inc. | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $46.66 | -10,595 | 7,132 | -60% | -$494,319 | |||||
| D | 2019-11-14 | RARX | Ra Pharmaceuticals, Inc. | Read Simon | Chief Scientific Officer | S - Sale+OE | $46.68 | -10,000 | 6,234 | -62% | -$466,808 | |||||
2019-11-15 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $27.28 | -5,000 | 1,246,204 | 0% | -$136,405 | ||||||
2019-11-18 | LPCN | Lipocine Inc. | Patel Mahesh V. | CEO, Pres | P - Purchase | $0.40 | +50,000 | 782,112 | +7% | +$20,095 | ||||||
| M | 2019-11-14 | NATR | Natures Sunshine Products Inc | Wynnefield Partners Small Cap Value LP | 10% | P - Purchase | $9.60 | +7,591 | 2,325,976 | 0% | +$72,866 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |